Search
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Products: LUCENTIS(10MG/ML), Lucentis 10mg/ml Solution for InjectionZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking
Dienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalIn Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions … It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself.
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigationalyears and older with a body weight of at least 40 kg. … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]
Rifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawn[A39986] Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease … [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]
Serdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants … Attention Deficit Hyperactivity Disorder (ADHD) is an early-onset neurodevelopmental disorder that often extends into adulthood and is characterized by developmentally inappropriate and impaired attention
Phenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIn the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]
Solriamfetol
go.drugbank.com/drugs/DB14754ApprovedInvestigationalSolriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated
Simethicone
go.drugbank.com/drugs/DB09512ApprovedInvestigational[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]
Mixtures: SIMFLAT 40MG/80 MG FİLM KAPLI TABLET, 90 ADET, BROMURO DE OTILONIO + SIMETICONA 40MG + 200MGProducts: Tablets 60mg, GASCOAL TABLET 50MG